Literature DB >> 26929776

Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology.

Matthew J Abrams1, Kevin Rakszawski2, Monali Vasekar2, Frank Passero1, Atif Abbas3, Yuxia Jia2, Muhammad Wasif Saif4.   

Abstract

Entities:  

Year:  2016        PMID： 26929776      PMCID： PMC4749860          DOI： 10.1177/1756283X15622601

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN： 1756-283X            Impact factor:   4.409


× No keyword cloud information.
  30 in total

1.  [Interpretation of the Chinese edition of NCCN Clinical Practice Guidelines in Oncology-Pancreatic Adenocarcinoma Guideline 2011].

Authors:  Yu-pei Zhao
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2011-09-01

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

3.  Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.

Authors:  William F Regine; Kathryn A Winter; Ross Abrams; Howard Safran; John P Hoffman; Andre Konski; Al B Benson; John S Macdonald; Tyvin A Rich; Christopher G Willett
Journal:  Ann Surg Oncol       Date:  2011-03-10       Impact factor: 5.344

4.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

5.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

Authors:  Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

6.  Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

Authors:  T M Breslin; K R Hess; D B Harbison; M E Jean; K R Cleary; A P Dackiw; R A Wolff; J L Abbruzzese; N A Janjan; C H Crane; J N Vauthey; J E Lee; P W Pisters; D B Evans
Journal:  Ann Surg Oncol       Date:  2001-03       Impact factor: 5.344

7.  DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.

Authors:  Timothy Hoey; Wan-Ching Yen; Fumiko Axelrod; Jesspreet Basi; Lucas Donigian; Scott Dylla; Maureen Fitch-Bruhns; Sasha Lazetic; In-Kyung Park; Aaron Sato; Sanjeev Satyal; Xinhao Wang; Michael F Clarke; John Lewicki; Austin Gurney
Journal:  Cell Stem Cell       Date:  2009-08-07       Impact factor: 24.633

Review 8.  Delta-like 4/Notch signaling and its therapeutic implications.

Authors:  Minhong Yan; Greg D Plowman
Journal:  Clin Cancer Res       Date:  2007-12-15       Impact factor: 12.531

9.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

10.  Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.

Authors:  Alix Portal; Simon Pernot; David Tougeron; Claire Arbaud; Anne Thirot Bidault; Christelle de la Fouchardière; Pascal Hammel; Thierry Lecomte; Johann Dréanic; Romain Coriat; Jean-Baptiste Bachet; Olivier Dubreuil; Lysiane Marthey; Laetitia Dahan; Belinda Tchoundjeu; Christophe Locher; Céline Lepère; Franck Bonnetain; Julien Taieb
Journal:  Br J Cancer       Date:  2015-09-15       Impact factor: 7.640
View more
  2 in total

1.  Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms.

Authors:  Annan Yang; Grit Herter-Sprie; Haikuo Zhang; Elaine Y Lin; Douglas Biancur; Xiaoxu Wang; Jiehui Deng; Josephine Hai; Shenghong Yang; Kwok-Kin Wong; Alec C Kimmelman
Journal:  Cancer Discov       Date:  2018-01-09       Impact factor: 39.397

2.  Clinical Practice Guidelines for Cryosurgery of Pancreatic Cancer: A Consensus Statement From the China Cooperative Group of Cryosurgery on Pancreatic Cancer, International Society of Cryosurgery, and Asian Society of Cryosurgery.

Authors:  Lihua He; Lizhi Niu; Nikolai N Korpan; Sajio Sumida; Yueyong Xiao; Jiaping Li; Barlian Sutedja; Youyong Lu; Jiansheng Zuo; Jianguo Liu; Kecheng Xu
Journal:  Pancreas       Date:  2017-09       Impact factor: 3.327
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.